

## ABCL MOC Exam Recommended Reading

If you are member of the National Lipid Association (NLA), all Journal of Clinical Lipidology (JCL) articles can be accessed by logging onto the NLA's website at [www.lipid.org](http://www.lipid.org) and then clicking on the "Journal of Clinical Lipidology" box on right-hand sidebar.

1. Bays HE, Jones PH, Orringer CE, Brown WV, Jacobson TA. National Lipid Association Annual Summary of Clinical Lipidology 2016. *J Clin Lipidol.* 2016;10(1 Suppl):S1-43. <https://www.ncbi.nlm.nih.gov/pubmed/26891998> **OPEN ACCESS FOR NLA MEMBERS**
2. Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. *J Clin Lipidol.* 2015;9(2):129-69. <https://www.ncbi.nlm.nih.gov/pubmed/25911072> **OPEN ACCESS FOR NLA MEMBERS**
3. Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. *J Clin Lipidol.* 2015;9(6 Suppl):S1-122. <https://www.ncbi.nlm.nih.gov/pubmed/26699442> **OPEN ACCESS FOR NLA MEMBERS**
4. American Diabetes Association. Standards of Medical Care in Diabetes –2016. *Diabetes Care.* 2016;39 Suppl 1:S1-S109. [http://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement\\_1.DC2/2016-Standards-of-Care.pdf](http://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement_1.DC2/2016-Standards-of-Care.pdf) **OPEN ACCESS**
5. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation.* 2009;120(16):1640-5. <https://www.ncbi.nlm.nih.gov/pubmed/?term=Alberti+Harmonizing> **OPEN ACCESS**
6. Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. *J Clin Lipidol.* 2014;8(3 Suppl):S47-57. <https://www.ncbi.nlm.nih.gov/pubmed/?term=Bays+Cohen+Statin+Safety+2014> **OPEN ACCESS FOR NLA MEMBERS**
7. Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. *J Clin Lipidol.* 2013;7(4):304-83. <https://www.ncbi.nlm.nih.gov/pubmed/23890517> **OPEN ACCESS FOR NLA MEMBERS**
8. Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). *Circulation.* 2016;133(9):849-58. <https://www.ncbi.nlm.nih.gov/pubmed/26801055> **OPEN ACCESS**
9. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med.* 2015;372(25):2387-97. <https://www.ncbi.nlm.nih.gov/pubmed/26444734> **OPEN ACCESS**
10. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and Safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010;376(9753):1670-81. <https://www.ncbi.nlm.nih.gov/pubmed/21067804> **OPEN ACCESS**
11. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet.* 2016;pii: S0140-6736(16)31357-5. <https://www.ncbi.nlm.nih.gov/pubmed/27616593>
12. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase 3 study. *Lancet.* 2013;381(9860):40-6.

- <https://www.ncbi.nlm.nih.gov/pubmed/23122768> **OPEN ACCESS**
13. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. *J Clin Lipidol*. 2011;5(5):338-67.
- <https://www.ncbi.nlm.nih.gov/pubmed/21981835> **OPEN ACCESS FOR NLA MEMBERS**
14. Del Gobbo LC, Falk MC, Feldman R, Lewis K., Mozaffarian D. Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials. *Am J Clin Nutr*. 2015;102(6):1347-56.
- <https://www.ncbi.nlm.nih.gov/pubmed/26561616> **OPEN ACCESS**
15. De Souza RJ, Mente A, Maroleanu A, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. *BMJ*. 2015;351:h3978.
- <https://www.ncbi.nlm.nih.gov/pubmed/26268692> **OPEN ACCESS**
16. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;63(25 Pt B):2960-84.
- <https://www.ncbi.nlm.nih.gov/pubmed/24239922> **OPEN ACCESS**
17. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med*. 2013;368(14):1279-90.
- <https://www.ncbi.nlm.nih.gov/pubmed/23432189> **OPEN ACCESS**
18. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128 Suppl 5:S213-56.
- <https://www.ncbi.nlm.nih.gov/pubmed/22084329> **OPEN ACCESS**
19. Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM. A systematic review of the usefulness of statin therapy in HIV-infected patients. *Am J Cardiol*. 2015;115(12):1760–6.
- <https://www.ncbi.nlm.nih.gov/pubmed/25907504>
20. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. *Circulation*. 2013;128(8):873-934.
- <https://www.ncbi.nlm.nih.gov/pubmed/?term=Fletcher+Ades+Kligfield> **OPEN ACCESS**
21. Giugliano RP, Sabatine MS. Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? *J Am Coll Cardiol*. 2015;65(24):2638-51.
- <https://www.ncbi.nlm.nih.gov/pubmed/26088304> **OPEN ACCESS**
22. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 Suppl 2):S49-73.
- <https://www.ncbi.nlm.nih.gov/pubmed/24222018> **OPEN ACCESS**
23. Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database Syst Rev*. 2015;(6):CD011737.
- <https://www.ncbi.nlm.nih.gov/pubmed/26068959>
24. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. *J Am Coll Cardiol*. 2014;63(25 Pt B):2985-3023.
- <https://www.ncbi.nlm.nih.gov/pubmed/24239920> **OPEN ACCESS**
25. Kellick KA, Bottorff M, Toth PP, The National Lipid Association's Safety Task F. A clinician's guide to statin drug-drug interactions. *J Clin Lipidol*. 2014;8(3 Suppl):S30-46.
- <https://www.ncbi.nlm.nih.gov/pubmed/?term=Kellick+Bottorff+Toth> **OPEN ACCESS FOR NLA MEMBERS**
26. Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N. An Assessment by the Statin Diabetes Task Force: 2014 Update. *J Clin Lipidol*. 2014;8(3 Suppl):S17-29.

<https://www.ncbi.nlm.nih.gov/pubmed/?term=Maki+Ridker+Brown+Statin+Diabetes>

**OPEN ACCESS FOR NLA MEMBERS**

27. Mansoor N, Vinknes KJ, Veierød MB, Retterstøl K. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. *Br J Nutr*. 2016;115(3):466-79.  
<https://www.ncbi.nlm.nih.gov/pubmed/26768850>
28. Martin SS, Blaha MJ, Elshazly MB, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. *J Am Coll Cardiol*. 2013; 62(8):732–739.  
<https://www.ncbi.nlm.nih.gov/pubmed/23524048> **OPEN ACCESS**
29. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2011;123(20):2292-333.  
<https://www.ncbi.nlm.nih.gov/pubmed/21502576> **OPEN ACCESS**
30. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J*. 2010;31(23):2844-53.  
<https://www.ncbi.nlm.nih.gov/pubmed/20965889> **OPEN ACCESS**
31. Rhodes KS, Weintraub M, Marchlewicz EH, Rubenfire M, Brook RD. Medical nutrition therapy is the essential cornerstone for effective treatment of "refractory" severe hypertriglyceridemia regardless of pharmaceutical treatment: Evidence from a Lipid Management Program. *J Clin Lipidol*. 2015;9(4):559-67.  
<https://www.ncbi.nlm.nih.gov/pubmed/26228674> **OPEN ACCESS FOR NLA MEMBERS**
32. Rojas-Fernandez CH, Goldstein LB, Levey AI, Taylor BA, Bittner V, The National Lipid Association's Safety Task Force. An assessment by the Statin Cognitive Safety Task Force: 2014 update. *J Clin Lipidol*. 2014;8(3 Suppl):S5-16.  
<https://www.ncbi.nlm.nih.gov/pubmed/24793442> **OPEN ACCESS FOR NLA MEMBERS**
33. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the Statin Muscle Safety Task Force: 2014 update. *J Clin Lipidol*. 2014;8(Suppl 3):S58-S71.  
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Rosenson+Baker+Statin+Muscle> **OPEN ACCESS FOR NLA MEMBERS**
34. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. *Circulation*. 2012;126(19):2283-92.  
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Stein+Dufour+Apolipoprotein+B> **OPEN ACCESS**
35. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;63(25 Pt B):2889-934.  
<https://www.ncbi.nlm.nih.gov/pubmed/24239923> **OPEN ACCESS**
36. Thompson PD, Arena R, Riebe D, Pescatello LS; American College of Sports Medicine. ACSM's new preparticipation health screening recommendations from ACSM's guidelines for exercise testing and prescription, ninth edition. *Curr Sports Med Rep*. 2013;12(4):215-7.  
<https://www.ncbi.nlm.nih.gov/pubmed/23851406>
37. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. *J Am Coll Cardiol*. 2016;67(20):2395-410.  
<https://www.ncbi.nlm.nih.gov/pubmed/27199064> **OPEN ACCESS**
38. Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. *J Clin Lipidol*. 2013;7(5):484-525.  
<https://www.ncbi.nlm.nih.gov/pubmed/24079290> **OPEN ACCESS FOR NLA MEMBERS**
39. Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. *Kidney Int*. 2014;85(6):1303-9.

<https://www.ncbi.nlm.nih.gov/pubmed/24552851>

40. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2016;68(1):92-125.  
<https://www.ncbi.nlm.nih.gov/pubmed/27046161> **OPEN ACCESS**